Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

XRTXBullishXORTX JPO patent Decision to Grantnews

Medium materiality6/10

XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

Nov 13, 2026, 12:05 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

JPO allowance creates formal patent protection in Japan for XRx-101, strengthening XORTX’s IP estate and potentially improving partnering or commercialization prospects there; the direct economic effect is conditional on successful registration, enforceability, and downstream partnering/commercialization.

AI summary

What happened, with direct paths to the underlying reporting

The Japan Patent Office issued a Decision to Grant a patent (JP Application No. 2022-556140) for XORTX’s XRx-101 program; allowed claims cover xanthine oxidase inhibitor compositions and the patent is expected to run until March 15, 2041 upon registration.

The Japan Patent Office issued a Decision to Grant a patent for Japanese Patent Application No. 2022-556140 supporting XRx-101.
The allowed claims are six claims directed to pharmaceutical compositions comprising a xanthine oxidase inhibitor, including oxypurinol, for treatment or prevention of acute kidney injury and other consequences of viral infection.
The Japanese Patent will issue upon payment of the registration fee and registration by the JPO.
Once registered, the Japanese Patent is expected to remain in force until March 15, 2041 (subject to annuities and any patent term extension).

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.